4 Results for "

wild-type c-MET

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "wild-type c-MET" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-50703
CAS No.: 917879-39-1
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-2461 is an ATP-competitive, selective and orally active wild-type and mutant c-Met inhibitor (IC50s: 0.4-2.5 nM). MK-2461 also inhibits Ron (IC50 of 7 nM) and Flt1 (IC50 of 10 nM), MK-2461 shows selective for c-MET over other kinases (lC50s = 22-7800 nM). MK-2461 can be used for the study of cancer, such as gastric cancer .
loading...
    loading...
Cat. No.: HY-P990947
CAS No.: 2868265-50-1
Synonyms: AZD9592 Antibody

Target:  

ADC Antibodies EGFR

Research Areas:  

Cancer

Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) .
loading...
    loading...
Cat. No.: HY-183672
Target:  

c-Met/HGFR

Research Areas:  

Cancer

c-Met-IN-28 is a type III allosteric inhibitor of c-MET, with pKi values of 7.4 (WT) and 7.1 (D1228V), and IC50 values of 37 nM (WT) and 72 nM (D1228V) against human c-MET. c-Met-IN-28 can be used for research on c-MET-driven cancers .
loading...
    loading...
Cat. No.: HY-181928
CAS No.: 3123529-62-1
Target:  

c-Met/HGFR PARP Apoptosis

Research Areas:  

Cancer

PARP1/c-Met-IN-3 (Compound L19) is a selective c-Met and PARP1 inhibitor, with an IC50 of 5.4 nM against c-Met and an IC50 of 3.7 nM against PARP1. PARP1/c-Met-IN-3 inhibits PARP2 enzymatic activity with an IC50 of 4.52 nM, and shows no specificity for PARP1 and PARP2. PARP1/c-Met-IN-3 induces cell cycle arrest and apoptosis. PARP1/c-Met-IN-3 exhibits anti-tumor activity against triple-negative breast cancer .
loading...
    loading...